[go: up one dir, main page]

WO2009074749A3 - Dérives de nicotinamide. leur préparation et leur application en thérapeutique - Google Patents

Dérives de nicotinamide. leur préparation et leur application en thérapeutique Download PDF

Info

Publication number
WO2009074749A3
WO2009074749A3 PCT/FR2008/001338 FR2008001338W WO2009074749A3 WO 2009074749 A3 WO2009074749 A3 WO 2009074749A3 FR 2008001338 W FR2008001338 W FR 2008001338W WO 2009074749 A3 WO2009074749 A3 WO 2009074749A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
preparation
hydrogen atom
therapeutic use
nicotinamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/001338
Other languages
English (en)
Other versions
WO2009074749A2 (fr
Inventor
Jerome Arigon
Claude Bernhart
Monsif Bouaboula
Pierre Casellas
Romain Combet
Samir Jegham
Sandrine Hllalret
Pierre Fraisse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08859496A priority Critical patent/EP2205566A2/fr
Priority to AU2008334457A priority patent/AU2008334457A1/en
Priority to CN200880109332A priority patent/CN101808996A/zh
Priority to CA2700559A priority patent/CA2700559A1/fr
Priority to MX2010003445A priority patent/MX2010003445A/es
Priority to JP2010526335A priority patent/JP2010540504A/ja
Priority to BRPI0817973-5A priority patent/BRPI0817973A2/pt
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of WO2009074749A2 publication Critical patent/WO2009074749A2/fr
Publication of WO2009074749A3 publication Critical patent/WO2009074749A3/fr
Priority to IL204663A priority patent/IL204663A0/en
Priority to US12/732,749 priority patent/US20100222319A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention est relative à un composé de formule (I) : dans laquelle : • A représente un groupe -NR1R'1 OU (C1-C6)aIcoxy; • Z et Z' représentent respectivement N et CH; N et CF; N et N; CH et CH; CH et N; • L représente un groupe -CH=CH- ou -CH2CH2- ou -(CH2)n-Y-; • R1 et R'1 sont tels que : (i) R1 représente : - un atome d'hydrogène; - un groupe aryle éventuellement substitué par un ou plusieurs atome(s) d'halogène; - un groupe hétéroaryle; - un groupe (C3-C6)cycloalkyle; - un groupe (C1-C6)alkyle et R'1 représente un atome d'hydrogène ou un groupe (C1-C6)alkyle; ou (ii) R1 et R'1 forment ensemble avec l'atome d'azote auquel ils sont reliés un groupe hétérocycloalkyle; • R2 représente un groupe -Q-R4; • Q représente un atome d'oxygène ou le groupe -NH-. • R4 représente : - un atome d'hydrogène; - un groupe hétéroaryle; - un groupe (C3-C6)cycloalkyle; - un groupe (C1-C6)alkyle, éventuellement substitué • R3 représente au moins un substituant du noyau pyridine.
PCT/FR2008/001338 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique Ceased WO2009074749A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2008334457A AU2008334457A1 (en) 2007-09-28 2008-09-26 Nicotinamide derivatives, preparation thereof and therapeutic use thereof
CN200880109332A CN101808996A (zh) 2007-09-28 2008-09-26 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用
CA2700559A CA2700559A1 (fr) 2007-09-28 2008-09-26 Derives de nicotinamide, leur preparation et leur application en therapeutique
MX2010003445A MX2010003445A (es) 2007-09-28 2008-09-26 Derivados de nicotinamida, su preparacion y su uso terapeutico.
JP2010526335A JP2010540504A (ja) 2007-09-28 2008-09-26 ニコチンアミド誘導体、これらの調製およびこれらの治療目的使用
EP08859496A EP2205566A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique
BRPI0817973-5A BRPI0817973A2 (pt) 2007-09-28 2008-09-26 derivados de nicotinamida, o respectivo preparo e a respectiva aplicação em terapêutica
IL204663A IL204663A0 (en) 2007-09-28 2010-03-22 Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
US12/732,749 US20100222319A1 (en) 2007-09-28 2010-03-26 Nicotinamide derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706799 2007-09-28
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/732,749 Continuation US20100222319A1 (en) 2007-09-28 2010-03-26 Nicotinamide derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2009074749A2 WO2009074749A2 (fr) 2009-06-18
WO2009074749A3 true WO2009074749A3 (fr) 2009-08-20

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001338 Ceased WO2009074749A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Country Status (19)

Country Link
US (1) US20100222319A1 (fr)
EP (1) EP2205566A2 (fr)
JP (1) JP2010540504A (fr)
KR (1) KR20100065165A (fr)
CN (1) CN101808996A (fr)
AR (1) AR066171A1 (fr)
AU (1) AU2008334457A1 (fr)
BR (1) BRPI0817973A2 (fr)
CA (1) CA2700559A1 (fr)
CL (1) CL2008002893A1 (fr)
FR (1) FR2921657A1 (fr)
IL (1) IL204663A0 (fr)
MX (1) MX2010003445A (fr)
PA (1) PA8797301A1 (fr)
PE (1) PE20091033A1 (fr)
RU (1) RU2010116765A (fr)
TW (1) TW200918056A (fr)
UY (1) UY31367A1 (fr)
WO (1) WO2009074749A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
US10851050B2 (en) 2016-06-22 2020-12-01 Fudan University Biaryl urea derivative or salt thereof and preparation process and use for the same

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2404919T3 (pl) 2005-11-08 2014-01-31 Vertex Pharma Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP
WO2008141119A2 (fr) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulateurs de cftr
RS55360B1 (sr) * 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
KR20160040745A (ko) 2007-12-07 2016-04-14 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CA2931134C (fr) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Derives heteroaryles convenant comme modulateurs du cftr
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
EP2440204B1 (fr) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Composés de nicotinamide utiles en tant que modulateurs de kinases
CA2791680A1 (fr) * 2010-03-01 2011-09-09 Myrexis, Inc. Composes et utilisations therapeutiques associees
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
EP4005559B1 (fr) 2010-04-07 2025-02-26 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-méthylpyriodin-2-yl) d'acide benzoïque et leur administration
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
PL2573073T3 (pl) * 2011-09-26 2015-04-30 Sanofi Sa Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
HRP20211194T1 (hr) 2014-11-18 2021-10-29 Vertex Pharmaceuticals Inc. Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
CN119775198A (zh) * 2018-05-04 2025-04-08 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
KR20220110744A (ko) * 2019-11-06 2022-08-09 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035864A1 (fr) * 1998-12-16 2000-06-22 Bayer Aktiengesellschaft Nouveaux composes de biphenyle et d'analogues de biphenyle utilises en tant qu'antagonistes d'integrines
WO2002048099A1 (fr) * 2000-12-16 2002-06-20 Merck Patent Gmbh Derives d'amides d'acides carboxyliques et leur utilisation dans le traitement de troubles thrombo-emboliques et de tumeurs
WO2005051366A2 (fr) * 2003-11-28 2005-06-09 Novartis Ag Derives de diaryluree utilises en traitement de maladies dependant de proteines kinases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035864A1 (fr) * 1998-12-16 2000-06-22 Bayer Aktiengesellschaft Nouveaux composes de biphenyle et d'analogues de biphenyle utilises en tant qu'antagonistes d'integrines
WO2002048099A1 (fr) * 2000-12-16 2002-06-20 Merck Patent Gmbh Derives d'amides d'acides carboxyliques et leur utilisation dans le traitement de troubles thrombo-emboliques et de tumeurs
WO2005051366A2 (fr) * 2003-11-28 2005-06-09 Novartis Ag Derives de diaryluree utilises en traitement de maladies dependant de proteines kinases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
US10851050B2 (en) 2016-06-22 2020-12-01 Fudan University Biaryl urea derivative or salt thereof and preparation process and use for the same

Also Published As

Publication number Publication date
US20100222319A1 (en) 2010-09-02
CN101808996A (zh) 2010-08-18
TW200918056A (en) 2009-05-01
WO2009074749A2 (fr) 2009-06-18
EP2205566A2 (fr) 2010-07-14
AR066171A1 (es) 2009-07-29
UY31367A1 (es) 2009-04-30
JP2010540504A (ja) 2010-12-24
PA8797301A1 (es) 2009-05-15
RU2010116765A (ru) 2011-11-27
KR20100065165A (ko) 2010-06-15
BRPI0817973A2 (pt) 2019-04-09
PE20091033A1 (es) 2009-08-17
FR2921657A1 (fr) 2009-04-03
CA2700559A1 (fr) 2009-06-18
MX2010003445A (es) 2010-04-27
AU2008334457A1 (en) 2009-06-18
IL204663A0 (en) 2010-11-30
CL2008002893A1 (es) 2009-10-16

Similar Documents

Publication Publication Date Title
WO2009074749A3 (fr) Dérives de nicotinamide. leur préparation et leur application en thérapeutique
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
EP1953154A4 (fr) Composes cinnamide de type morpholine
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
WO2008155668A3 (fr) Composés hétéroarylamide pyrimidone
NO20053600L (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
TN2009000081A1 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2- α ] PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
WO2008145839A8 (fr) Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique
WO2008108380A3 (fr) Composés de pyrrole
WO2009144395A8 (fr) DÉRIVÉS POLYSUBSTITUES DE 2-HETEROARYL-6-PHENYL-IMIDAZO[1,2- α]PYRIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
NO20080738L (no) Fremgangsmater for neurobeskyttelse
WO2009156864A3 (fr) Dérivés pyrimidin-4-one à substitution alkyle
WO2009095792A3 (fr) Dérivés d'hétéroarylamide diazépinopyrimidone substitués
WO2008136444A1 (fr) Dérivé hétérocyclique fusionné
WO2009069736A1 (fr) Composé azoté
WO2010033643A3 (fr) Composés à petite molécule pour la différenciation de cellules souches
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
WO2008155670A3 (fr) Composés d'arylamide de pyrimidone
WO2008155669A3 (fr) Dérivés de pyrimidone arylamide
WO2008153042A1 (fr) Agent antitumoral

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880109332.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859496

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 204663

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2700559

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1081/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107006595

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010526335

Country of ref document: JP

Ref document number: MX/A/2010/003445

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008334457

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008334457

Country of ref document: AU

Date of ref document: 20080926

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008859496

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010116765

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0817973

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100326